^
Association details:
| Biomarker: | ADAM9 underexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy
Excerpt:
To investigate the functional relevance between the change in ADAM9 mRNA expression and clinical response, the serum levels of ADAM9 mRNA were followed during the nivolumab therapy...responders exhibited a significant decrease in ADAM9 mRNA (C, Subject #9, from 573.98 ± 5.16 to 523.85 ± 7.0 (p < 0.05) after 2 cycles, and further down to 262.58 ± 20.13 (p < 0.05) after 4 cycles...In our study, the change of serum ADAM9 mRNA was easily correlated with the clinical response to nivolumab, while the observed lymphocyte immunophenotype changes were intriguing but not enough to draw a solid conclusion...
DOI:
https://doi.org/10.3390/cancers12030745
